Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting - Corvus Pharma (NASDAQ:CRVS)

BURLINGAME, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. CRVS, a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that it will present preclinical and early clinical data from its Phase 1/1b clinical trial of CPI-818 at the American Society of Hematology (ASH) 61st Annual Meeting 2019 in Orlando, Florida, taking place December 7-10, 2019.

Corvus will present data on CPI-818 in two poster sessions:

Poster Presentations:

Poster 1571:	Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor that Preferentially Blocks the Growth of T Lymphoma Cells.
Presenter:	Patrick Ng, PhD, Corvus Senior Scientist
Poster Session:	625: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster I
Date and Time:	Saturday, December 7 from 5:30 pm – 7:30 pm ET
Location:	Poster Hall / Hall B, Level 2 / Orange County Convention Center

Poster 4030:	A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2 Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma.
Presenter:	Mehrdad Mobasher, M.D., Corvus Vice President and Chief Medical Officer
Poster Session:	624: Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Poster III
Date and Time:	Monday, December 9, 2019 from 6:00 pm – 8:00 pm ET
Location:	Poster Hall / Hall B, Level 2 / Orange County Convention Center

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus' lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and blockade of adenosine production. These candidates are being studied in ongoing Phase 1 and 2 clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant, and with pembrolizumab. The Company's third clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
650-900-4522
LLea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
W2O pure
+1 213-262-9390
sseapy@purecommunications.com

Market News and Data brought to you by Benzinga APIs